Immunovant (IMVT) cash on hand

Cash · fiscal 2026
$902.11M

Immunovant (IMVT) held cash of $902.11M at the end of fiscal 2026 (March 31, 2026). That is 26.4% higher than the $713.97M of fiscal 2025. Figures as of 17 Nov 2026, 22:06 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2026
$902.11M
Change on fiscal 2025
+26.4%
Highest on record
$902.11Mfiscal 2026
Lowest on record
$376.53Mfiscal 2023
Fiscal years on record
42023–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant cash on hand, in more detail

Across the 4 fiscal years on record (2023–2026), the highest was $902.11M in fiscal 2026 and the lowest $376.53M in fiscal 2023.

History · 4 fiscal years

Cash by fiscal year

Immunovant cash on hand, year by year

Immunovant (IMVT) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2026$902.11M 26.4% up
2025$713.97M 12.4% up
2024$635.37M 68.7% up
2023$376.53M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Immunovant and comparable companies
CompanyCashFiscal year
Bausch + Lomb BLCO$383.00M2025
Amneal Pharmaceuticals AMRX$282.03M2025
Caris Life Sciences CAI$798.57M2025
Immunovant IMVT$902.11M2026
Axsome Therapeutics AXSM$322.93M2025
Chemed CHE$74.52M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant cash on hand: questions and answers

How much cash does Immunovant have?

Immunovant (IMVT) held cash of $902.11M at the end of fiscal 2026 (March 31, 2026). That is 26.4% higher than the $713.97M of fiscal 2025.

What are the highest and lowest cash figures on record for Immunovant?

Across the 4 fiscal years on record (2023–2026), the highest was $902.11M in fiscal 2026 and the lowest $376.53M in fiscal 2023.

How is Immunovant's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) cash on hand”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.